MSFT 435.0 0.7061% AAPL 230.65 -1.2924% NVDA 139.965 -0.9097% GOOGL 176.965 4.2934% GOOG 178.65 4.3882% AMZN 193.73 1.5197% META 594.31 0.1736% AVGO 177.28 -1.0935% TSLA 262.2401 1.0481% TSM 195.14 -0.914% LLY 831.501 -7.977% V 291.3 3.3418% JPM 224.685 0.8008% UNH 564.77 0.4696% NVO 113.15 1.0448% WMT 81.58 -0.1469% LVMUY 134.2 -1.4033% XOM 117.0342 -0.2096% LVMHF 670.0 -1.3008% MA 513.51 1.4281%

Abcam plc

Healthcare US ABCZF

22.25USD
-(-%)

Last update at 2024-10-29T13:30:00Z

Day Range

22.2522.25
LowHigh

52 Week Range

5.0023.80
LowHigh

Fundamentals

  • Previous Close 22.25
  • Market Cap5120.86M
  • Volume0
  • P/E Ratio2225.00
  • Dividend Yield0.91%
  • EBITDA106.00M
  • Revenue TTM379.70M
  • Revenue Per Share TTM1.66
  • Gross Profit TTM 270.50M
  • Diluted EPS TTM0.01

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -15.60000M 4.70M 25.40M 8.40M 56.40M
Minority interest - - - - -
Net income -8.50000M 4.40M 16.20M 12.50M 45.00M
Selling general administrative 224.50M 189.70M 147.40M 118.30M 88.90M
Selling and marketing expenses 224.50M 189.70M - 118.30M 88.90M
Gross profit 270.50M 224.60M 211.80M 180.20M 183.20M
Reconciled depreciation 52.90M 41.00M 35.40M 29.90M 15.40M
Ebit -10.20000M 6.40M 33.60M 36.50M 77.60M
Ebitda 42.70M 47.40M 64.00M 66.40M 93.00M
Depreciation and amortization 52.90M 41.00M - 29.90M 15.40M
Non operating income net other - - - - -
Operating income -10.10000M 7.10M 36.50M 10.50M 56.10M
Other operating expenses 371.80M 308.30M - 224.10M 182.90M
Interest expense 5.40M 1.70M 3.20M 2.80M 0.30M
Tax provision -7.10000M 0.30M 9.20M -4.10000M 11.40M
Interest income 0.40M 0.30M 0.40M 0.70M 0.60M
Net interest income -5.50000M -2.40000M -2.80000M -2.10000M 0.30M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -7.10000M 0.30M 5.60M -4.10000M 11.40M
Total revenue 361.70M 315.40M 297.70M 260.00M 259.90M
Total operating expenses 280.60M 217.50M 261.20M 144.30M 106.20M
Cost of revenue 91.20M 90.80M 85.90M 79.80M 76.70M
Total other income expense net -5.50000M -2.40000M -8.90000M -25.30000M -20.90000M
Discontinued operations - - - - -
Net income from continuing ops -8.50000M 4.40M 16.20M 12.50M 45.00M
Net income applicable to common shares -8.50000M 4.40M 25.60M 12.50M 45.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 1056.60M 986.10M - 811.40M 446.70M
Intangible assets 227.90M 234.20M - 154.40M 106.70M
Earning assets - - - - -
Other current assets 8.10M 0.50M 0.30M -0.30000M 0.20M
Total liab 329.70M 330.00M - 308.80M 61.90M
Total stockholder equity 726.90M 656.10M - 502.60M 384.80M
Deferred long term liab - - - - -
Other current liab 50.60M 45.90M 10.10M 2.10M 3.50M
Common stock 0.50M 0.50M 0.50M 0.40M 0.40M
Capital stock 0.50M 0.50M - 0.40M 0.40M
Retained earnings 300.70M 289.60M 271.70M 255.70M 260.10M
Other liab 32.10M 41.50M 27.60M 28.30M 16.60M
Good will 398.30M 364.80M - 192.80M 120.90M
Other assets 12.10M 10.40M 15.60M 13.70M 9.40M
Cash 89.00M 95.10M - 187.30M 87.10M
Cash and equivalents - - - - -
Total current liabilities 201.80M 187.20M 52.00M 159.60M 45.30M
Current deferred revenue 7.30M - - 0.90M -
Net debt 134.90M 134.60M - 46.90M -87.10000M
Short term debt 128.10M 128.40M - 113.70M -
Short long term debt 119.60M 119.20M - 106.40M -
Short long term debt total 223.90M 229.70M - 234.20M -
Other stockholder equity 267.50M 366.00M 94.20M 135.70M 24.20M
Property plant equipment 159.70M 161.70M 157.30M 164.70M 37.10M
Total current assets 255.40M 211.50M 306.20M 278.80M 171.80M
Long term investments 3.20M - - 7.00M 0.80M
Net tangible assets 100.70M 57.10M 293.00M 155.80M 157.20M
Short term investments - - - - -
Net receivables 90.30M 52.60M 40.40M 50.80M 48.50M
Long term debt - - - - -
Inventory 68.00M 58.20M 42.90M 40.70M 36.00M
Accounts payable 15.80M 12.90M 13.80M 43.80M 41.80M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 158.20M - - 110.80M 100.10M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 3.50M - - 274.90M
Deferred long term asset charges - - - - -
Non current assets total 801.20M 774.60M - 532.60M 274.90M
Capital lease obligations 104.30M 110.50M - 127.80M -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -24.40000M -0.10000M -0.10000M -2.20000M -2.20000M
Change to liabilities -6.20000M 6.20M 7.20M 2.40M 7.70M
Total cashflows from investing activities -24.40000M -291.50000M -44.40000M -148.10000M -49.90000M
Net borrowings -11.30000M 111.20M -221.60000M 100.20M 100.20M
Total cash from financing activities -15.50000M 111.40M 30.00M 184.60M -24.70000M
Change to operating activities - - - - -
Net income -10.10000M 7.10M 25.60M 10.50M 56.10M
Change in cash -6.10000M -116.80000M 49.20M 100.20M -3.10000M
Begin period cash flow 95.10M 211.90M 187.30M 87.10M 90.20M
End period cash flow 89.00M 95.10M 219.90M 187.30M 87.10M
Total cash from operating activities 28.70M 62.90M 66.60M 63.00M 70.20M
Issuance of capital stock 1.10M 3.20M 127.40M 111.20M 1.40M
Depreciation 52.90M 41.00M 35.40M 29.90M 15.40M
Other cashflows from investing activities 0.70M 13.50M 4.60M 0.10M 5.10M
Dividends paid 0.00000M - - 25.00M 24.90M
Change to inventory -7.40000M -6.20000M -7.00000M -1.10000M -6.10000M
Change to account receivables -33.30000M 4.00M -15.40000M 2.70M -6.10000M
Sale purchase of stock -0.20000M 0.00000M -0.10000M -0.10000M -0.20000M
Other cashflows from financing activities -5.10000M 108.20M -2.20000M 250.60M -1.00000M
Change to netincome 31.20M 13.50M 24.20M 16.80M 14.30M
Capital expenditures 41.30M 59.80M 23.00M 35.70M 40.40M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -46.90000M 4.00M -0.30000M 4.00M -4.50000M
Stock based compensation 23.30M 17.90M 13.60M 9.30M 6.50M
Other non cash items 9.50M -7.10000M -1.40000M 9.30M -3.30000M
Free cash flow -12.60000M 3.10M 14.70M 27.30M 29.80M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABCZF
Abcam plc
- -% 22.25 2225.00 31.55 13.49 5.63 13.95 85.14
NVO
Novo Nordisk A/S
1.17 1.04% 113.15 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
1.95 1.76% 112.70 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
3.92 0.83% 474.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
-1.92 0.21% 925.41 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam plc operates as a subsidiary of Danaher Corporation.

Abcam plc

Discovery Drive, Cambridge, United Kingdom, CB2 0AX

Key Executives

Name Title Year Born
Mr. Alan Thomas Hirzel BS, M.B.A., M.S., MBA, MS CEO & Exec. Director 1968
Mr. Michael Shaun Baldock B.A. CFO & Director 1964
Mr. Mark Dermody Interim CIO NA
James Staveley VP of Investor Relations NA
Marc Perkins Gen. Counsel & Company Sec. NA
Emma Sceats Sr. VP of Sales, Service & Bus. Devel. NA
Mr. Nick Skinner Sr. VP of HR NA
Mr. Mark Bushfield Sr. VP of Research & Innovation NA
Ms. Kirstie Speck BBusSc Head of Consumer Insights NA
Ms. Yvonne Chien Sr. VP of Customer Experience NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.